Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.

ABSTRACT: Palivizumab was the first antiviral monoclonal antibody (mAb) approved for therapeutic use in humans, and remains a prophylactic treatment for infants at risk for severe disease because of respiratory syncytial virus (RSV). Palivizumab is an engineered humanized version of a murine mAb targeting antigenic site II of the RSV fusion (F) protein, a key target in vaccine development. There are limited reported naturally occurring human mAbs to site II; therefore, the structural basis for human antibody recognition of this major antigenic site is poorly understood. Here, we describe a nonneutralizing class of site II-specific mAbs that competed for binding with palivizumab to postfusion RSV F protein. We also describe two classes of site II-specific neutralizing mAbs, one of which escaped compe

SUBMITTER: Mousa JJ 

PROVIDER: S-EPMC5098655 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature